NanoViricides, Inc. is a development stage company with a unique nanomedicine technology. The Company is developing nanotechnology-based biomimetic anti-viral medicines, that we call "nanoviricides®". Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. seasonal and potentially-epidemic influenzas and bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature
Community Manager, Dealslands.co.uk
Sales Account Executive, Springer Nature
Director of Sales , SOLABS
Managing Director, Thoroughly Good Consulting